Medicortex Finland Oyj is a biotechnology company dedicated to developing diagnostics and treatments for acute neurodegenerative conditions, including traumatic brain injury (TBI) and concussion. One of the company's missions is to identify a new biomarker in order to reliably assess the severity and extent of brain injury. Medicortex was founded by Dr. Adrian Harel in Turku, Finland, in 2014 and it operates as a public limited company. Dr. Harel has a track record in business management and leadership of early-stage biotechnology companies. ---- Kuvaus suomeksi: Medicortex Finland Oyj (http://www.medicortex.fi) on bioteknologian alan yritys, joka on keskittynyt parantamaan tapaturmaisten aivovammojen (TBI) diagnostiikkaa ja hoitoa. Yrityksen nykyinen painopiste on kehittää biomerkkiaineisiin perustuvaa diagnostiikkaa, jolla pystytään arvioimaan aivovamman laajuutta ja vaikeusastetta.